Literature DB >> 33505466

Genotype-Phenotype Correlation in Patients with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency in Cuba.

Tania Mayvel Espinosa Reyes1, Teresa Collazo Mesa1, Paulina Arasely Lantigua Cruz2, Adriana Agramonte Machado2, Emma Domínguez Alonso1, Henrik Falhammar3,4.   

Abstract

BACKGROUND: There are several studies that show a good genotype-phenotype correlation in congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD). However, there is well-documented evidence of inconsistency in some cases.
OBJECTIVES: To determine if there is a correlation between the identified mutations and the clinical manifestations of 21OHD in the Cuban population.
METHODS: A cross-sectional descriptive study of all patients referred for a molecular diagnosis of 21OHD in Cuba from January 2000 to December 2018. The clinical manifestations of each patient were identified and classified according to the phenotype. The CYP21A2 gene was analyzed for the presence of 5 point mutations involved in the pathogenesis of 21OHD (intron 2, deletion of 8bp, I172N, P30L, and Q318X); correlation was sought between the phenotypic characteristics and the frequencies of point mutations in the patients using the Spearman test.
RESULTS: A total of 55 patients underwent direct analysis of the CYP21A2 gene in order to determine the presence of the 5 point mutations. Point mutations were identified in 31 patients, which corresponded to 56%. A statistically significant genotype-phenotype correlation was found.
CONCLUSIONS: The correlation between the detected molecular defect and the clinical expression of 21OHD was reasonable in the Cuban population, which could allow phenotypic predictions to be made from the genotype.
Copyright © 2021 Tania Mayvel Espinosa Reyes et al.

Entities:  

Year:  2021        PMID: 33505466      PMCID: PMC7806372          DOI: 10.1155/2021/9316284

Source DB:  PubMed          Journal:  Int J Endocrinol        ISSN: 1687-8337            Impact factor:   3.257


  30 in total

1.  Detection of a frequent duplicated CYP21A2 gene carrying a Q318X mutation in a general population with quantitative PCR methods.

Authors:  Maher Kharrat; Awatef Riahi; Faouzi Maazoul; Ridha M'rad; Habiba Chaabouni
Journal:  Diagn Mol Pathol       Date:  2011-06

2.  Steroid 21-hydroxylase gene mutational spectrum in 454 Argentinean patients: genotype-phenotype correlation in a large cohort of patients with congenital adrenal hyperplasia.

Authors:  Roxana Marino; Pablo Ramirez; Jesica Galeano; Natalia Perez Garrido; Carlos Rocco; Marta Ciaccio; Diana M Warman; Gabriela Guercio; Eduardo Chaler; Mercedes Maceiras; Ignacio Bergadá; Mirta Gryngarten; Viviana Balbi; Esther Pardes; Marco A Rivarola; Alicia Belgorosky
Journal:  Clin Endocrinol (Oxf)       Date:  2011-10       Impact factor: 3.478

3.  [Recommendations for the diagnosis and treatment of classic forms of 21-hydroxylase-deficient congenital adrenal hyperplasia].

Authors:  Amparo Rodríguez; Begoña Ezquieta; José Igancio Labarta; María Clemente; Rafael Espino; Amaia Rodriguez; Aranzazu Escribano
Journal:  An Pediatr (Barc)       Date:  2017-02-01       Impact factor: 1.500

4.  Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany.

Authors:  N Krone; A Braun; A A Roscher; D Knorr; H P Schwarz
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

Review 5.  Clinical outcomes in the management of congenital adrenal hyperplasia.

Authors:  Henrik Falhammar; Marja Thorén
Journal:  Endocrine       Date:  2012-01-07       Impact factor: 3.633

6.  Analysis of steroid 21-hydroxylase gene mutations in the Spanish population.

Authors:  B Ezquieta; A Oliver; R Gracia; P G Gancedo
Journal:  Hum Genet       Date:  1995-08       Impact factor: 4.132

7.  Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.

Authors:  Phyllis W Speiser; Wiebke Arlt; Richard J Auchus; Laurence S Baskin; Gerard S Conway; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; M Hassan Murad; Sharon E Oberfield; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

Review 8.  Congenital adrenal hyperplasia.

Authors:  Diala El-Maouche; Wiebke Arlt; Deborah P Merke
Journal:  Lancet       Date:  2017-05-30       Impact factor: 79.321

Review 9.  Clinical outcomes and characteristics of P30L mutations in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Mirjana Kocova; Violeta Anastasovska; Henrik Falhammar
Journal:  Endocrine       Date:  2020-05-05       Impact factor: 3.633

10.  Increased Risk of Autoimmune Disorders in 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study.

Authors:  Henrik Falhammar; Louise Frisén; Angelica Linden Hirschberg; Agneta Nordenskjöld; Catarina Almqvist; Anna Nordenström
Journal:  J Endocr Soc       Date:  2019-04-10
View more
  1 in total

Review 1.  Characteristics of In2G Variant in Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.

Authors:  Mirjana Kocova; Paola Concolino; Henrik Falhammar
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-24       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.